BioCentury
ARTICLE | Company News

NeuroSearch, Carlsson Research deal

August 28, 2006 7:00 AM UTC

NEUR plans to acquire fellow CNS company Carlsson Research for SEK166 million ($23.1 million) in cash and SEK84 million ($11.7 million) in stock. Carlsson shareholders are eligible for up to an additional SEK625 million ($87.1 million) in milestones. The acquisition would give NEUR ACR16, a dopamine stabilizer that is expected to start Phase III testing for Huntington's disease (HD) next year. The compound also is in Phase I testing for schizophrenia and has Orphan Drug designation in the U.S. and Europe for HD. Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) has rights to ACR16 for schizophrenia. ...